Lenz Therapeutics’ Eye Disease Drugs Meet Main Goal Of Late-stage Study

Lenz Therapeutics said on Wednesday its experimental drugs to treat loss of near vision met the main goal of a late-stage study, sending its shares up nearly 23% before the...
Reuters Health Information

Full Story →